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evice Closure of Muscular Ventricular
eptal Defects Using the Amplatzer
uscular Ventricular Septal Defect Occluder
mmediate and Mid-Term Results of a U.S. Registry
alf Holzer, MD,* David Balzer, MD, FACC,† Qi-Ling Cao, MD,* Ken Lock, BS,‡
iyad M. Hijazi, MD, MPH, FACC,* for the Amplatzer Muscular Ventricular Septal Defect Investigators
hicago, Illinois; St. Louis, Missouri; and Golden Valley, Minnesota
OBJECTIVES We sought to report the results of a U.S. registry of device closure of congenital muscular
ventricular septal defects (VSDs) using the new Amplatzer mVSD occluder (AGA Medical
Corp., Golden Valley, Minnesota).
BACKGROUND Muscular VSDs pose a significant surgical challenge with increased morbidity and mortality.
METHODS Data were prospectively collected from 83 procedures involving 75 patients who underwent
an attempt of percutaneous (70 [93.3%] of 75) and/or perventricular (surgical) (6 [8.0%] of
75) device closure of hemodynamically significant muscular VSDs. The patients’ median age
was 1.4 years (range 0.1 to 54.1 years). Outcome parameters were procedural success, evidence
of residual shunts on echocardiography, and occurrence of procedure-related complications.
The median follow-up was 211 days (range 1 to 859 days).
RESULTS The median size of the primary VSD was 7 mm (range 3 to 16 mm) and in 34 of 78 (43.6%)
procedures, patients had multiple VSDs (range 2 to 7). The device was implanted successfully
in 72 of 83 (86.7%) procedures. In 17 of 83 (20.5%) procedures, multiple devices were
implanted (range 2 to 3). Procedure-related major complications occurred in 8 of 75 (10.7%)
patients. Device embolization occurred in two patients and cardiac perforation in one patient.
There were two (2.7%) procedure-related deaths. The 24-h postprocedural complete closure
rate was 47.2% (34 of 72 patients), increasing to 69.6% (32 of 46 patients) at 6 months and
92.3% (24 of 26 patients) at 12 months. Six patients underwent successful closure using the
perventricular surgical (beating heart) approach, with complete closure at day 1 in three
patients and trivial/small residual shunts in the remainder of the patients.
CONCLUSIONS The Amplatzer mVSD device (AGA Medical Corp.) offers excellent closure rates and low
mortality when used to close congenital muscular VSDs. The device appears to be safe and
effective. (J Am Coll Cardiol 2004;43:1257–63) © 2004 by the American College of
Cardiology FoundationV
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aurgical closure of muscular ventricular septal defects
VSDs) still poses a significant surgical challenge (1). They
re frequently hidden within the coarse right ventricular
RV) trabeculations and, therefore, are difficult to localize
hrough the standard surgical approach via the right atrium.
arious different surgical approaches have been proposed;
owever, overall mortality and the rate of residual VSDs
emain higher than with isolated perimembranous VSDs
1–4).
Device closure of VSDs has been used since the late
980s (5–8). In 1997, Sideris et al. (8) reported their
xperience using the buttoned device. They were able to
uccessfully implant the device in 18 of 25 (72%) cases.
hirteen of 18 (72%) patients had complete occlusion of the
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GA Medical Corp., and Mr. Lock is an employee, who runs the clinical trials, of
GA Medical Corp., which manufactures the device.
Manuscript received May 17, 2003; revised manuscript received September 30,a003, accepted October 6, 2003.SD and 2 of 18 (11%) patients required surgical removal of
he device (migration/tilting). In 1999, Janorkar et al. (6)
eported the use of the Rashkind device (USCI Angio-
raphics, Billerica, Massachusetts) to close muscular VSDs
ith residual shunts in 5 of 16 (31%) patients and
rocedure-related deaths in 2 of 16 (12.5%) patients. In
999, the Amplatzer mVSD occluder (AGA Medical
orp., Golden Valley, Minnesota) was added to the already
xisting investigational devices for percutaneous closure of
SDs (9). Initial results were promising (10–12).
The objective of this study was to prospectively evaluate
he safety and efficacy of the muscular VSD occluder in its
linical use to close congenital muscular VSDs.
ETHODS
tudy population. The study was conducted as a prospec-
ive, nonrandomized, interventional registry involving 14
.S. tertiary referral centers (Appendix). The study was
pproved by the institutional review board of each center
nd by the U.S. Food and Drug Administration under a
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Device Closure of Muscular VSD April 7, 2004:1257–63ponsor-initiated Investigational Device Exemption. After
he investigators had been selected, qualified, and trained,
uscular VSD patients who were eligible for closure were
nrolled. A monitor was used to oversee the compliance
ith the study protocol.
The inclusion criteria for device closure included: 1) the
resence of a hemodynamically significant muscular VSD
demonstrated by echocardiography or angiography); and 2)
atients with muscular VSD and a history of infective
ndocarditis.
Left ventricular (LV) enlargement on echocardiography
as considered an important finding, but ultimately, the
ecision as to which VSD was considered hemodynamically
ignificant was left up to the principal investigator at each
articipating institution. Patients with multiple VSDs/
Swiss cheese” VSDs were included in the study.
Exclusion criteria included patients with a weight below
kg, irreversible pulmonary vascular disease (7 U/m2),
epsis, contraindications to antiplatelet therapy, a perimem-
ranous VSD location, or a distance to the semilunar valves
f 4 mm. Patients who previously underwent pulmonary
rtery banding were included, irrespective of the LV dimen-
ions, either for a perventricular approach at the time of
urgical debanding or for transcatheter VSD device closure.
nce a patient met the enrolment criteria, he/she or the
uardian was fully informed of the available treatment
ptions. The final decision to participate in the study was
ade by the patient and/or guardian.
Between August 2000 and January 2003, 75 patients were
ncluded in the study on an intention-to-treat basis. Two
atients had a history of endocarditis.
ata collection. Data were collected prospectively at the
ime of the procedure at each participating institution by the
esponsible Amplatzer investigator and submitted to a
entral data base at the Research Division of AGA Medical
orp. Collected data included demographic details (date of
rocedure, age, gender, height, weight), symptoms and
igns (congestive heart failure, failure to thrive, recurrent
espiratory tract infections, sepsis, heart murmur), electro-
ardiographic (ECG) details (LV hypertrophy, RV hyper-
rophy, biventricular hypertrophy, arrhythmias), echocar-
iographic details (size and number of VSDs, location of
SDs, left atrial/RV/LV enlargement, classification of
hunt), procedure details (access route, sheath size, heparin,
uoroscopy time, procedure time, balloon sizing), surgical
Abbreviations and Acronyms
CXR  chest X-ray
ECG electrocardiogram
LV  left ventricle/ventricular
RV  right ventricle/ventricular
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
VSD  ventricular septal defectetails (surgical approach, cardiopulmonary bypass, proce- pure time), and some additional information (medication,
spirin, coagulopathy, pulmonary vascular disease, anaesthe-
ia). The collected data also included follow-up data at 1
ay, 1 month, 6 months, 12 months, 24 months, and 36
onths after the procedure, regarding echocardiographic
ndings, ECG details, and the presence of a murmur. For
ny adverse event occurring at the time of or subsequent to
evice implantation, information was obtained by the local
mplatzer investigator with regard to the circumstances,
reatment, outcome, device, or procedure relation, as well as
lassification as minor or major. Where data were inconclu-
ive or raised additional questions, the local investigator was
irectly contacted and asked for clarification. The accuracy
f the submitted data was audited for each participating
nstitution using source documents (catheter reports, case
otes), which were analyzed by monitors from AGA Med-
cal Corp. during control visits to these institutions. Local
xperienced pediatric echocardiographers at each participat-
ng institution interpreted all echocardiographic data in a
onblinded fashion.
easured outcome parameters. The measured outcome
arameters were procedural success, as defined by device
elease in the appropriate position without embolization,
omplete closure or quantification of a residual shunt, as
ssessed by color Doppler echocardiography, and the occur-
ence of procedure- or device-related complications and
ther adverse events during the follow-up period. Measur-
ng the width of the color jet as it exited through the
entricular septum was used to assess the degree of a residual
hunt. It was classified as trivial for a width 1 mm, small
or a width between 1 and 2 mm, moderate for a width
etween 2 and 4 mm, and large for a width 4 mm, in a
ay similar to the technique used to describe atrial level
hunts after device closure (13).
evice. The Amplatzer mVSD occluder (AGA Medical
orp.) is made of nitinol wire. It is a self-expandable device
onsisting of two flat disks that are linked via a central
onnecting waist, the diameter of which determines the size
f the device. The two disks are 4 mm larger than the
onnecting waist. Dacron fabric is incorporated into each
isk to enhance thrombosis. Further details have been
escribed in previous reports (10,11). It requires a 6F to 9F
heath for delivery, depending on the size of the device,
hich is available from 4 to 18 mm.
losure protocol. The procedures were performed rou-
inely under general anesthesia. The protocol we used for
ranscatheter closure of muscular VSDs has been described
n details in previous reports (11). Figure 1 demonstrates the
ifferent steps of percutaneous device closure. Six patients
nderwent closure of their defects in the operating room
nder continuous transesophageal echocardiography (TEE)
uidance. Technical details of intraoperative perventricular
evice closure of VSDs have been reported elsewhere (14).
ll patients had a chest X-ray (CXR), transthoracic echo-
ardiography (TTE), and ECG within 24 h after the
rocedure. The follow-up protocol included assessments at
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April 7, 2004:1257–63 Device Closure of Muscular VSD, 6, 12, and 24 months. All visits included a routine
hysical examination, as well as CXR (optional at 6
onths), ECG (optional at 6 and 12 months), and TTE.
atients were routinely maintained on aspirin or equivalent
ntiplatelet therapy for the duration of six months after the
rocedure.
tatistical analysis. Basic descriptive statistical reports
mean and median values, variance, standard deviation, and
ange) were obtained for each parameter, using StatsDirect
oftware (StatsDirect Ltd, Sale, Cheshire, United King-
om). We used nonparametric tests to compare patient
ariables, such as weight, number of VSDs, and VSD size,
ith outcome parameters, such as procedural success
Mann-Whitney U test), residual shunt (Kendal rank cor-
elation), procedure and fluoroscopy time (Kendal rank
orrelation), and the occurrence of complications (Kendal
ank correlation). All tests were performed at alpha  5%.
ESULTS
eventy-five patients were enrolled in the study and under-
ent a total of 83 procedures. Thirty-nine of 75 (52.0%)
igure 1. Cine fluoroscopic images in a seven-month-old female baby wi
ercutaneous device closure. (A) Left ventricular (LV) angiogram in the fou
uoroscopic image in the straight frontal projection, demonstrating the gu
nferior vena cava. The wire was snared from there and exteriorized into the
nside (arrow), passing from the right internal jugular vein through the VS
gainst the septum (arrow). (E) Left ventricular angiogram confirms good
nd RV disk (arrow). (G) Cine fluoroscopic image after the device was rele
hunting through the device.atients were female. The median age of the patients at the bime of the procedure was 1.5 years (range 0.1 to 54.1 years).
n 26 of 76 (34.2%) procedures, the patient had a history of
ongestive heart failure and in 22 of 76 (89.9%) procedures,
he patient had a history of failure to thrive. Twenty-eight
f 75 (37.3%) patients had previous cardiac surgery, such as
ulmonary artery banding in 12 patients, an attempt at surgical
SD closure in 11 patients, ligation of a patent ductus
rteriosus in four, and coarctation repair in 3 patients.
Either LV, RV, or biventricular hypertrophy was present
efore the procedure on 53 of 71 (74.6%) ECGs. The
resence of multiple VSDs was demonstrated by TTE in 34
f 78 (43.6%) procedures (range 2 to 7 VSDs). The median
ize of VSD on echocardiography was 7 mm (range 3 to 16
m). An enlarged LV, RV, or left atrium was present on
he echocardiogram in 74 of 83 (89.1%) procedures.
Based on our echocardiographic and angiographic data,
he primary VSD was located anterior in 10 of 79 (12.7%)
efects, apical in 11 (13.9%), mid-muscular in 26 (32.9%),
nd posterior in 2 (2.5%). The 30 remaining VSDs (37.9%)
ere located within combined/multiple septal regions. An
levated pulmonary vascular resistance above 3 U/m2 but
2
gle muscular ventricular septal defect (VSD), demonstrating the steps of
mber view, demonstrating a 6-mm mid-muscular VSD (arrow). (B) Cine
ire (arrow) across the VSD into the right ventricular (RV) and down the
internal jugular vein. (C) Delivery sheath with an 8-mm Amplatzer device
terminating into the LV. (D) The LV disk is being deployed and pulled
sk position. (F) Cine angiogram after deployment of the connecting waist
(H) Final LV angiogram confirming good device position and no residualth sin
r-cha
ide w
right
D and
LV di
ased.elow 7 U/m was present in 10 of 80 (12.5%) procedures.
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Device Closure of Muscular VSD April 7, 2004:1257–63Six patients underwent closure of their defects in the
perating room under continuous TEE guidance. The VSD
as approached through a RV free wall puncture without
ardiopulmonary bypass (14). Cardiopulmonary bypass was
sed to correct associated lesions after VSD closure in three
atients. All procedures were successful (device released)
sing a single device, and early complete closure at day 1 was
chieved in 3 of 6 (50%) patients; the remainder had trivial
r small residual leaks. Follow-up data up to 12 months
fter implantation were available for two patients: one
ithout a residual VSD at 12 months after the procedure
nd one with still a small residual shunt.
Seventy-seven of 83 (92.8%) procedures were transcath-
ter attempts of VSD device closure; 74 of 76 (97.4%) of
hese were performed under general endotracheal anesthesia
Table 1). The procedure was successful (device inserted and
eleased) in 66 of 77 (85.7%). Repeated percutaneous
rocedures for unsuccessful attempted closure or residual
SDs were required in 7 of 70 (10%) patients. A total of 88
evices were implanted in the 77 transcatheter procedures to
lose 144 VSDs. The median fluoroscopy time was 54.2 min
range 8.8 to 356 min), and the median total procedure time
as 181 min (range 44 to 584 min). Balloon sizing of the
efect was optional and was used in 9 of 76 (11.8%) cases.
here data were available in 42 of 75 procedures, the
edian size of the sheath used for device delivery was 7F
range 5F to 9F). The first disk was deployed in the RV in
of 74 (6.7%) procedures and in the LV in 70 of 74 (94.6%)
rocedures. The device was deployed via the internal jugular
ein in 43 of 69 (62.3%) procedures and via the femoral vein
n 26 of 69 (37.7%) procedures. During one procedure, the
rst device deployed was from the RV, and another device
as deployed from the LV. The median device size was 8
m (range 4 to 16 mm). We used two devices in 12 of 66
18.2%) procedures and three devices in 5 of 66 (7.6%)
rocedures. The maximum number of devices implanted in
ny one patient was six over two separate procedures.
able 1. Basic Procedural Data of Percutaneous Device Closure
f Ventricular Septal Defects Via the Transcatheter Approach
n  77 Procedures)
econd/third attempt at closure (repeat) 7/77 (9.1%)
eneral anesthesia 74/76 (97.4%)
luoroscopy time (min) 54.2 (8.8–356)
alloon sizing 9/76 (11.8%)
irst disk deployed in RV 5/74 (6.7%)
irst disk deployed in LV 70/74 (94.6%)
elivery via jugular vein 43/69 (62.3%)
elivery via femoral vein 26/69 (37.7%)
evice used (mm) 8 (4–16)
rocedural success 66/77 (85.7%)
umber devices used 144
1 49/66 (74.2%)
2 12/66 (18.2%)
3 5/66 (7.6%)
ata are presented as the n/N (%) of procedures or the median value (range).
LV  left ventricle; RV  right ventricle.Table 2 summarizes the adverse events of the procedure. Ftotal of 59 adverse events or complications related to the
rocedure or device occurred in 34 of 75 (45%) patients.
ight of 75 (10.7%) of them had major complications. Two
f 75 (2.7%) patients died as a direct result of the procedure.
n one patient, a cardiac perforation occurred secondary to
he delivery sheath being too close to the free wall, and the
evice was deployed in the pericardium. This patient un-
erwent emergency surgical repair but sustained severe
erebral damage, and support was finally withdrawn. An-
ther patient sustained a cardiac arrest resulting in cerebral
nsult secondary to the use of a larger sheath for retrieval of
he device, which caused significant blood loss. A third
atient died suddenly at home of an unknown cause five
onths after the last of three transcatheter procedures. This
atient had systemic pulmonary artery pressure despite
losure of 13 separate ventricular communications (5 devices
nd 8 coils). On autopsy, the heart appeared to be hyper-
rophied and enlarged, and all devices and coils were in good
osition.
Device embolization occurred in 2 of 75 (2.7%) patients,
oth of which were successfully retrieved. One device was
etrieved surgically (the patient was going to have elective
ricuspid repair and the Maze procedure for atrial flutter)
nd one in the catheter laboratory percutaneously. Hypo-
ensive episodes and/or cardiac arrest requiring inotropic
upport occurred in 9 of 75 (12%) patients. Arrhythmias or
onduction abnormalities were encountered in 15 of 75
20%) of patients, consisting of right bundle branch block (n
2), second- or third-degree heart block (n  6), ventric-
lar tachycardia (n  3), junctional rhythm (n  3), and
pisodes of bradycardia (n  4). Most of these were
emporary, but 2 of 75 (2.7%) patients developed permanent
ight bundle branch block. The described arrhythmias
onsist of those submitted to the central database as adverse
vents and likely do not include very transient nonsustained
rrhythmias encountered during catheter manipulation.
able 2. Adverse Events After Device Closure of Muscular
entricular Septal Defects (n  75 Patients)
rocedure-related complications 28/75 (37.3%)
Arrhythmia/conduction anomalies 15/75 (20.0%)
Hypotension/cardiac arrest 9/75 (12.0%)
Hematoma/pseudoaneurysm/TX 5/75 (6.7%)
CVA/TIA 3/75 (4.0%)
Equipment/technical issues 3/75 (4.0%)
Device embolization 2/75 (2.7%)
Cardiac perforation 1/75 (1.3%)
Other 5/75 (6.7%)
eath 3/75 (4.0%)
Procedure-related 2/75 (2.7%)
Unrelated/unknown 1/75 (1.3%)
nresolved complications (alive) 6/75 (7.89%)
RBBB 2/75 (2.63%)
LVOT gradient 2/75 (2.63%)
Stroke 1/75 (1.31%)
ata are presented as the n/N (%) of patients.
CVA  cerebrovascular accident; LVOT  left ventricular outflow tract; RBBB
right bundle branch block; TIA  transient ischemic attack; TX  transfusion.ive of 75 (6.7%) patients required blood transfusion due to
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April 7, 2004:1257–63 Device Closure of Muscular VSDignificant blood loss. One patient presented with a tran-
ient ischemic attack 24 h after the procedure. A brain
omputed tomographic scan was negative. Two of 75 (2.7%)
atients had minor device-related gradients across the LV
utflow tract (gradient 15 mm Hg), neither of which
equired any form of intervention.
A lower weight of the patient at the time of the
rocedure significantly correlated with an increased risk
f procedure- or device-related complications (p 
.007). Procedure- or device-related complications were
ncountered in 7 of 13 (53.8%) procedures undertaken in
atients weighing 5 kg, comparable to 24 of 63 (38.1%)
rocedures in patients weighing 5 kg. The median
eight of patients who had unsuccessful percutaneous
rocedures was 6.5 kg, whereas the median weight of
atients who had a successful procedure was 9.4 kg.
owever, this difference was not statistically significant
p  0.07). There was a statistically significant negative
orrelation between weight at the time of the procedure
nd a residual postprocedural shunt (p  0.03). However,
o significant correlation could be established between
he number of VSDs and a residual shunt (p  0.35). The
umber of VSDs (p  0.65) and size of the primary VSD
p  0.11) were not significant risk factors for the
ccurrence of complications. However, patients with a
arger number of VSDs tended to require significantly
onger fluoroscopy times (p  0.002) and procedure times
p  0.0004). Patients with a lower weight also required
ignificantly longer fluoroscopy times (p  0.0006).
The median follow-up was 211 days (range 1 to 859
ays). After 24 h from the procedure, the VSD was
ompletely closed in 34 of 72 (47.2%) cases. Moderate or
arge residual shunts were present in 5 of 72 (6.9%) cases.
he shunt closure rates (Table 3) improved as the time from
losure to follow-up increased. At one month, the complete
losure rate was 58.7% (37 of 63); at 6 months, it was 69.6%
32 of 46); and at 12 months, it was 92.3% (24 of 26). No
atient had moderate or large residual shunts at 12- or
4-month follow-up. Between hospital discharge and one-
ear follow-up, the shunts improved from trivial to none in
ight patients, from small to none in four patients, and from
able 3. Follow-Up After Device Closure of Muscular Ventricula
Postimplantation
(n  72)
1 Day
(n  72)
urmur — 39/71
CG: LVH/RVH/BVH — 45/70
CG: arrhythmia — 20/71
hunt on echocardiography n  72 n  72
Closed 27 34
Trivial 17 13
Small 25 20
Moderate 2 4
Large 1 1
ollow-up median (days)
VH  biventricular hypertrophy; ECG  electrocardiography; LVH  left ventrioderate to none in two patients. One trivial shunt re- rained unchanged, and in one patient, a trivial shunt that
as not previously present was identified.
ISCUSSION
his series reports the largest cohort of patients with
uscular VSDs who underwent device closure. The success
ates (complete closure or any residual shunt 2 mm) have
een very good (100% at 12 months and 2 years), although
he interpretation of these results has to be regarded with
ome caution, as only 38% completed the one-year follow-
p. In contrast, the rate of reoperation for residual VSDs
fter surgical closure has been reported to be as high as 5%
o 10% (1,4,15).
The early mortality (30 days) in our population was 2.7%,
hich compares well to the results after surgical correction
f muscular VSDs, which has been reported to be as high as
% to 17% (1,4). However, in 1998, Kitagawa et al. (15)
eported 0% mortality in 33 patients with multiple muscular
SDs.
Closing VSDs using the Amplatzer mVSD device (AGA
edical Corp.) is a fairly new technique, and as such, each
perator will have a learning curve in using this device. With
ncreasing experience, ventricular perforations, such as the
ne leading to death in one of our patients, may potentially
e preventable in the future.
Other complications encountered were short-lived and
esolved without residual morbidity in most of the patients.
he rate of permanent conduction disturbances of 2.6% is
elow the incidence after surgical closure of VSDs (16).
owever, current data on the incidence of conduction
isturbances solely after the closure of muscular VSDs is not
vailable, and therefore comparisons are difficult to make. In
wo patients, a mild gradient across the LV outflow tract
eveloped. This could be avoided in future cases by allowing
larger distance to the semilunar valves or by using the
mplatzer membranous VSD device (AGA Medical Corp.)
or anterior muscular VSDs with only a minimal muscular
im to the aortic valve.
Various other devices have been used in the past to close
SDs. In the introduction, we referred to reported rates of
ptal Defects: Echocardiographic and Clinical Data
1 Month
(n  66)
6 Months
(n  48)
12 Months
(n  29)
24 Months
(n  12)
28/64 14/45 10/28 2/11
30/58 13/31 5/22 5/10
17/60 8/31 4/22 3/10
n  63 n  46 n  26 n  10
37 32 24 8
10 6 2 1
14 6 0 1
1 0 0 0
1 2 0 0
211 (1–859)
ypertrophy; RVH  right ventricular hypertrophy.r Seesidual shunting of 28% using the Sideris device and 31%
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Device Closure of Muscular VSD April 7, 2004:1257–63sing the Rashkind device. Compared with these previously
sed devices and the CardioSEAL device (NMT Medical,
oston, Massachusetts), the Amplatzer mVSD occluder
AGA Medical Corp.) has the following advantages: a small
elivery system and excellent control by the operator, with
he ability to recapture the device before release.
The indications for using the Amplatzer mVSD device
AGA Medical Corp.) are not limited by patient size or
SD size, although the chances of procedural success are
educed. Some larger and multiple VSDs were successfully
losed using larger devices up to 16 mm, as well as by the
bility to use multiple devices (17). In our series, we were
ble to percutaneously close VSDs in children as small as 3.2
g. However, the decision for device closure in a child
eighing 5 kg should be made very carefully. The in-
reased risk of residual shunts and procedure-related com-
lications requires a very experienced operator and a firm
ndication for this approach. Weight, although not statisti-
ally significant, was lower in the group with primarily
nsuccessful procedures. This is an important consideration,
s other factors of poor procedural success (number of
SDs, size of VSDs, location of VSDs) were not evident
rom our data.
In addition to the obvious advantages (no scar, less pain
nd discomfort, no cardiopulmonary bypass), the percuta-
eous approach has additional advantages, including a
horter hospital stay, whereas surgical VSD closure usually
nvolves a hospital stay of no 4 days. Procedural costs may
ell be below the standard surgical approach. However, this
ould need to be more formally addressed in a prospective
ost analysis study.
Our data demonstrate that perventricular device closure is
easible. In particular, the subgroup of patients who under-
ent pulmonary artery banding for large muscular VSDs
ay benefit from such an approach of combining pulmonary
rtery debanding with perventricular device closure of
SDs. However, the number of involved patients is insuf-
cient to draw any strong conclusions.
tudy limitations. Our study has some limitations. Pa-
ients were not randomized between surgical and percuta-
eous closure, and as such, a comparison between the two
pproaches may be biased. Our follow-up data are incom-
lete, and long-term conclusions cannot be made at this
tage. In addition, restrictive muscular VSDs with only mild
V volume loading would be conservatively managed by
any institutions, thereby trying to avoid any invasive
rocedure. Also, interventional closure is not a simple
echnique. The challenge of advancing a wire through the
SD into a position where snaring is feasible, as well as the
ifficulties in advancing a sheath through the VSD without
inking or causing damage to adjacent structures, should
ot be underestimated. The procedure requires considerable
echnical operator skills, which may only be obtained and
aintained in larger institutions. The technical challenge of
his procedure is reflected in the relatively long procedure
nd fluoroscopy times.onclusions. Our study has demonstrated excellent clo-
ure rates and low mortality using the Amplatzer mVSD
evice (AGA Medical Corp.) to close congenital muscular
SDs. The device appears to be safe and effective. The
ncidence of permanent morbidity after this procedure is
ow. However, patient selection (weight, VSD size and
ocation) and an experienced operator are very important for
rocedural success. Device closure using the Amplatzer
VSD device (AGA Medical Corp.) should be considered
n important alternative to the surgical approach in treating
ongenital muscular VSDs.
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PPENDIX
or a complete list of the Amplatzer mVSD device inves-
igators, please see the April 7, 2004, issue of JACC at
ww.cardiosource.com/jacc.html.
